Argentinian health groups oppose monopoly patents on remdesivir drug for coronavirus treatment
July 9, 2020: US pharmaceutical giant Gilead has filed five patent applications for a 20-year monopoly on the manufacture and commercialisation of the drug remdesivir in Argentina. Remdesivir is the first drug approved globally to treat people infected with COVID-19. If the National Institute of Industrial Property (INPI) rejects the patent, it would be a significant step toward Argentina being able to manufacture remdesivir locally at a reduced price.
